Added to YB: 2025-09-29
Pitch date: 2025-09-25
IMRX [bullish]
Immuneering Corporation
-17.48%
current return
Author Info
Truffle Pigs, written by the co-founders of Kipps Capital, shares in-depth reports on companies they believe are significantly undervalued. Sign up for the newsletter.
Company Info
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients.
Market Cap
$383.7M
Pitch Price
$8.18
Price Target
N/A
Dividend
N/A
EV/EBITDA
-5.75
P/E
-4.92
EV/Sales
N/A
Sector
Biotechnology
Category
value
Immuneering’s Extraordinary 86% 9-Month OS Marks a Breakthrough in 1L PDAC
IMRX: Phase 2a pancreatic cancer data shows 86% 9-month OS vs 47% SOC, suggesting ~23 months median OS (double SOC). Superior safety vs competitors. 90%+ discount to RVMD despite stronger 1L survival data. Pulse DCI platform prevents resistance, expanding to NSCLC with Lilly/Regeneron partnerships.
Read full article (4 min)